Evaluation of safety and pharmacokinetics of administering intravenous busulfan in twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 9, 2002, Pages 486-492

  Fernandez, Hugo F ^a   Tran, Hai T ^a   Albrecht, Federico ^a   Lennon, Shari ^a   Caldera, Humberto ^a   Goodman, Mark S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Intravenous busulfan; Pharmacokinetics; Transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PHENYTOIN; TACROLIMUS; ANTINEOPLASTIC AGENT; BUCY 2 PROTOCOL; BUCY-2 PROTOCOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BODY WEIGHT; CATHETER INFECTION; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPISTAXIS; EVALUATION; FATIGUE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; INSOMNIA; LEUKOCYTE COUNT; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LONG TERM CARE; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYCOSIS; NAUSEA; NONHODGKIN LYMPHOMA; PNEUMONIA; PREDICTION; REPRODUCIBILITY; SEIZURE; SEPSIS; STEM CELL TRANSPLANTATION; SUDDEN DEATH; THROMBOCYTE COUNT; VOMITING; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG TOXICITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036402048     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12374453     Document Type: Article

References (33)

1. Haddow A, Timmis GM. Myleran in chronic myeloid leukemia. Lancet. 1953;1:207-208.
2. Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst. 1974;53:1781-1785.
3. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309: 1347-1353.
4. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382-1388.
5. Geller RB, Saral R, Piantadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood. 1989;73: 2209-2218.
6. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BuCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:383-389.
7. Ringden O, Labopin M, Tura S, et al. A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;93:637-645.
8. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen; a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85: 2263-2268.
9. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan/cyclophosphamide as preparative regimens for bone marrow transplant in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood. 1993;81: 2187-2193.
10. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994;84:2144-2150.
11. Schuler U, Schroer S, Kühnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 1994;14:759-765.
12. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
13. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics and busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
14. Slattery JP, Sanders JE, Buckner CD, et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
15. Andersson BS, Bhagwatwar H, Chow D. Parenteral Busulfan for treatment of malignant disease. US patents 5,430,057, 1995, and 5,559,148, 1996.
16. Bhagwatwar H, Phadungponja S, Chow D, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37:401-408.
17. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pre-transplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000;6:548-554.
18. Andersson BS, Ashwin K, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematological malignancy prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8:145-154.
19. Dix SP, Bucur SZ, Mullins RE, et al. Studies of the pharmacokinetics and toxicity of once daily bolus intravenous busulfan in non-human primates [abstract]. Blood. 1995;86(suppl 1). Abstract 888.
20. Deeg HJ, Schuler VS, Shulman H, et al. Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model. Biol Blood Marrow Transplant. 1999;5:316-321.
21. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood. 1994;84:2357-2362.
22. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 2000;26:463-470.
23. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetics. Comput Programs Biomed. 1979;9:115-134.
24. Common Toxicity Criteria. Version 2.0. Available at: http://ctep. info.nih.gov/reporting/ctc.html.
25. Jones RJ, Lee KS, Beschorner WE, et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation. 1975;44:778-783.
26. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:832-843, 895-902.
27. Fernandez HF, Tran HT, Albrecht F, et al. Evaluation of safety, efficacy and pharmacokinetics of administering IV busulfan (Busulfex®) in patients with advanced hematologic malignancies undergoing stem cell transplant (SCT) [abstract]. Biol Blood Marrow Transplant. 2001;7:71. Abstract 29.
28. Ljungman P, Hassan M, Bekassy AN. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997;20:909-913.
29. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203-6207.
30. Kashyap A, Wingard J, Cagnoni S, et al. Intravenous (IV) vs. oral busulfan (BU) as part of Bu/Cy (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): decreased incidence of hepatic veno-occlusive disease (VOD) [abstract]. Blood. 1999;94(suppl 1):321b. Abstract 4661.
31. Lindley C, Shord S, McCune J, et al. Test dose and traditional first dose therapeutic drug monitoring for busulfan (BU) fail to accurately predict steady-state systemic exposure in allogeneic bone marrow transplantation patients. Proc Am Soc Clin Oncol. 2001;20:9a. Abstract 31.
32. Bolinger A, Zangwill A, Slattery J, et al. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract]. Blood. 1999;94(suppl 1):145a. Abstract 635.
33. Vaughan W, Carey D, Salzman D, Soong S. Validation of a limited sampling strategy (LSS) for pharmacokinetically directed dosing of high-dose intravenous busulfan (Busulfex) in BMT preparative regimens [abstract]. Biol Blood Marrow Transplant. 2001;7:92. Abstract 106.